Clinical trials: Arrhythmogenic Cardiomyopathy
Arrhythmogenic Right Ventricular Cardiomyopathy
The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
The diagnosis of Arrhythmogenic right ventricular cardiomyopathy can be difficult. The 80 lead ECG may increase the specificity and sensitivity in diagnosing this potentially life threatening inherited cardiac condition.
- Trial name
- NCT02291393
- Testing
- 80 lead ECG
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Arrhythmogenic Right Ventricular Cardiomyopathy
Athlete's Heart or Arrhythmogenic Right Ventricular Cardiomyopathy: Contribution of Exercise Cardiovascular Magnetic Resonance (CMR)
Prospective, nonrandomized, single-center, comparative study to define if right ventricular (RV) contractile reserve assessed by exercise CMR helps to improve the differential diagnosis between pathological and physiological…
- Trial name
- CA2VD (NCT05024708)
- Testing
- Cardiac exercises and tests
- Where
- France
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy
Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy
Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left ventricular systolic dysfunction (left ventricular…
- Conditions
- Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Arrhythmia, Hypertrophic Cardiomyopathies
- Trial name
- IMPROVE-NICM (NCT06730464)
- Where
- 4 sites in Italy, Portugal and 1 more
- Volunteers
- 500 people
- Sponsor
- Centro Medico Teknon
Arrhythmogenic Right Ventricular Cardiomyopathy
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
- Trial name
- RIDGE-1 (NCT06228924)
- Testing
- TN-401
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tenaya Therapeutics
Arrhythmogenic Cardiomyopathy
Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE)
This study aims to identify novel inflammatory biomarkers in AC, whether in circulating blood, in situ or as imaging biomarkers to better understand the pathophysiology of the disease and then to determine contribution to the…
- Trial name
- ACORE (NCT05569356)
- Testing
- Prospective, Retrospective
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Right Ventricle Abnormality
The Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
The arrhythmogenic right ventricular cardiomyopathy, also known as arrhythmogenic right ventricular dysplasia (ARVC/D) is a rare myocardial disease with a prevalence estimated to range from 1 case on 5000 persons in the general…
- Trial name
- NCT03900208
- Testing
- Hystological analysis of ventricular tissue
- Volunteers
- 10 people
- Sponsor
- University of Campania Luigi Vanvitelli
Myocarditis, Ventricular Arrythmia
GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis.
This study aims to answer multiple unsolved questions in the field of arrhythmic myocarditis. Improving the diagnostic work-up. While endomyocardial biopsy (EMB) and cardiac magnetic resonance (CMR) constitute the gold standard…
- Trial name
- GEAM (NCT06889662)
- Where
- Italy
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Scientific Institute San Raffaele
Inherited Cardiac Arrhythmias, Long QT Syndrome
Long Term Monitoring for Risk of Sudden Death
Risk prediction in in inherited heart rhythm conditions that may cause sudden cardiac arrest or death is difficult. Sometimes the risks may be low but the loss of life in an otherwise healthy young individual is catastrophic.
- Conditions
- Inherited Cardiac Arrhythmias, Long QT Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy, Brugada Syndrome
- Trial name
- NCT04124237
- Where
- Canada
- Volunteers
- 1,051 people
- Sponsor
- University of British Columbia
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
- Trial name
- NCT05885412
- Testing
- RP-A601
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
The purpose of this trial is to study the genetic and phenotypic aspects of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C), and determine the impact of genetic testing in clinical practice.
- Trial name
- DVDA (NCT00999947)
- Where
- France
- Volunteers
- 351 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Ventricular Tachycardia (VT)
Treatment Registry of Arrhythmias, Complications and Electrocardiograms in Arrhythmogenic CardioMyopathies
TRACE-ACM is a multicenter, retrospective, observational study of patients with arrhythmogenic cardiomyopathy who received an implantable cardioverter-defibrillator (ICD) and had documented ventricular tachyarrhythmias.
- Conditions
- Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Ventricular Tachycardia (VT), Ventricular Fibrillation, ICD
- Trial name
- TRACE-ACM (NCT07688200)
- Volunteers
- 300 people
- Sponsor
- Policlinico Casilino ASL RMB
Arrhythmogenic Right Ventricular Cardiomyopathy
National ARVC Data Registry and Bio Bank
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited condition that may cause life threatening irregular heart rhythms that often manifest as unexpected cardiac arrest or sudden death in early adulthood.
- Trial name
- ARVCRegistry (NCT01804699)
- Where
- 16 sites in Canada
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Heart Diseases, Arrhythmogenic Right Ventricular Dysplasia
Multidisciplinary Study of Right Ventricular Dysplasia
The purpose of this study is to investigate the cardiac, clinical, and genetic aspects of arrhythmogenic right ventricular dysplasia (ARVD), a progressive disorder that predominantly affects the right side of the heart and causes…
- Trial name
- NCT00024505
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- University of Arizona
Arrhythmogenic Cardiomyopathy, PKP2-ACM
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2)…
- Conditions
- Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
- Trial name
- GRIT-PKP2 (NCT07050160)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lexeo Therapeutics
Arrhythmogenic Cardiomyopathy (AC, ARVD/C)
Cardiac Rehabilitation in Patients With High-Genetic-Risk Arrhythmogenic Cardiomyopathy: The HGEN-CARE-AC Trial
The goal of this clinical trial is to evaluate a structured and personalized cardiac rehabilitation program for patients diagnosed with arrhythmogenic cardiomyopathy (ACM) who carry high-risk genetic mutations.
- Trial name
- HGEN-CARE-AC (NCT07708311)
- Testing
- Cardiac Rehabilitation Programme
- Volunteers
- 70 people
- Sponsor
- Juan Jiménez Jáimez
Atrial Fibrillation, Stroke
Left Atrial Appendage Arrhythmogenic and Thrombogenic Substrate
The purpose of the project is to elucidate whether it is possible to identify which patients are at risk of forming blood clots that can cause stroke based on analysis of the electrocardiogram.
- Trial name
- LAATAS (NCT06405750)
- Testing
- left atrial appendage closure
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP).
- Conditions
- Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy
- Trial name
- TORCH-Plus (NCT04265040)
- Where
- Germany
- Volunteers
- 2,040 people
- Sponsor
- University Hospital Heidelberg
Cardiomyopathies, Amyloidosis Cardiac
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging…
- Conditions
- Cardiomyopathies, Amyloidosis Cardiac, Fabry Disease, Arrhythmogenic Cardiomyopathy
- Trial name
- CMPMIRNA (NCT06813443)
- Where
- 3 sites in Italy
- Volunteers
- 700 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Arrhythmogenic Right Ventricular Dysplasia
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV).
- Trial name
- BRAVE (NCT03593317)
- Testing
- Spironolactone
- Where
- 13 sites in France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Dilated Cardiomyopathy
The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
Midwall septal fibrosis (MSF) is a common structural abnormality in non-ischaemic dilated cardiomyopathy (DCM). Its presence is believed to increase the risk of malignant ventricular arrhythmias (VA), but the mechanism of…
- Trial name
- DCM-MSF (NCT05026112)
- Testing
- ECG-Imaging, Cardiac MRI scan
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University College, London